Working... Menu
Trial record 16 of 1308 for:    survival | Neuroendocrine Tumors

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03279601
Recruitment Status : Recruiting
First Posted : September 12, 2017
Last Update Posted : September 12, 2017
Information provided by (Responsible Party):
Shen Lin, Peking University

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 1, 2019
  Estimated Study Completion Date : September 1, 2020